Cardiotoxicity of Anticancer Drugs

An analysis of the literature for 2022 was carried out in order to study the latest data on the cardiotoxicity of antitumor drugs. The abundance of data on the pathogenesis of cardiotoxicity of even a single chemotherapeutic agent indicates the multifactorial effect and the characteristics of the in...

Full description

Saved in:
Bibliographic Details
Main Authors: I. Maiborodin, A. O. Shumeikina, V. I. Maiborodina, S. E. Krasilnikov
Format: Article
Language:Russian
Published: LLC "Publishing House OKI" 2025-02-01
Series:Антибиотики и Химиотерапия
Subjects:
Online Access:https://www.antibiotics-chemotherapy.ru/jour/article/view/1190
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849244490024353792
author I. Maiborodin
A. O. Shumeikina
V. I. Maiborodina
S. E. Krasilnikov
author_facet I. Maiborodin
A. O. Shumeikina
V. I. Maiborodina
S. E. Krasilnikov
author_sort I. Maiborodin
collection DOAJ
description An analysis of the literature for 2022 was carried out in order to study the latest data on the cardiotoxicity of antitumor drugs. The abundance of data on the pathogenesis of cardiotoxicity of even a single chemotherapeutic agent indicates the multifactorial effect and the characteristics of the individual sensitivity of each patient to a particular drug. Due to the multifactorial nature of the pathogenesis of cardiotoxicity, the clinical manifestations of this complication are also numerous. It should be taken into account that oncological patients could have suffered from various cardiovascular diseases even before tumor development, and that cancer progression even without therapeutic intervention, or before it, can cause cardiac side effects. To identify such processes, it is necessary to monitor cardio-oncological patients in dynamics. When conducting conservative cancer treatment and in the event of the development of side effects, the complete cancellation of treatment is impossible, as it is necessary to continue the therapy, as well as repeat its courses, often throughout the patient's life. In this regard, methods are needed to reduce the severity of the cardiotoxic effect, as well as suppress the adverse effects of anticancer drugs on the myocardium, and the search and development of effective methods for the prevention and treatment of cardiotoxicity of chemotherapy drugs are still relevant. Timely detection, and hence, prevention, as well as reduction of the degree of damaging effects of the beginning cardiotoxic effect when using cancer chemotherapy agents is possible only with close cooperation between oncologists and cardiologists.
format Article
id doaj-art-f1df4b6d00124cccafaca72a36de12f4
institution Kabale University
issn 0235-2990
language Russian
publishDate 2025-02-01
publisher LLC "Publishing House OKI"
record_format Article
series Антибиотики и Химиотерапия
spelling doaj-art-f1df4b6d00124cccafaca72a36de12f42025-08-20T03:59:08ZrusLLC "Publishing House OKI"Антибиотики и Химиотерапия0235-29902025-02-01699-109110710.37489/0235-2990-2024-69-9-10-91-1071068Cardiotoxicity of Anticancer DrugsI. Maiborodin0A. O. Shumeikina1V. I. Maiborodina2S. E. Krasilnikov3Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of The Russian Academy of SciencesFederal Research Center for Fundamental and Translational Medicine of the Ministry of Science and Higher Education of the Russian FederationInstitute of Chemical Biology and Fundamental Medicine, Siberian Branch of The Russian Academy of SciencesFederal Research Center for Fundamental and Translational Medicine of the Ministry of Science and Higher Education of the Russian FederationAn analysis of the literature for 2022 was carried out in order to study the latest data on the cardiotoxicity of antitumor drugs. The abundance of data on the pathogenesis of cardiotoxicity of even a single chemotherapeutic agent indicates the multifactorial effect and the characteristics of the individual sensitivity of each patient to a particular drug. Due to the multifactorial nature of the pathogenesis of cardiotoxicity, the clinical manifestations of this complication are also numerous. It should be taken into account that oncological patients could have suffered from various cardiovascular diseases even before tumor development, and that cancer progression even without therapeutic intervention, or before it, can cause cardiac side effects. To identify such processes, it is necessary to monitor cardio-oncological patients in dynamics. When conducting conservative cancer treatment and in the event of the development of side effects, the complete cancellation of treatment is impossible, as it is necessary to continue the therapy, as well as repeat its courses, often throughout the patient's life. In this regard, methods are needed to reduce the severity of the cardiotoxic effect, as well as suppress the adverse effects of anticancer drugs on the myocardium, and the search and development of effective methods for the prevention and treatment of cardiotoxicity of chemotherapy drugs are still relevant. Timely detection, and hence, prevention, as well as reduction of the degree of damaging effects of the beginning cardiotoxic effect when using cancer chemotherapy agents is possible only with close cooperation between oncologists and cardiologists.https://www.antibiotics-chemotherapy.ru/jour/article/view/1190oncologycardiologycardiooncologycancercardiotoxicitypathogenesis of cardiotoxicitydiagnosis of cardiotoxicitysuppression of cardiotoxicity
spellingShingle I. Maiborodin
A. O. Shumeikina
V. I. Maiborodina
S. E. Krasilnikov
Cardiotoxicity of Anticancer Drugs
Антибиотики и Химиотерапия
oncology
cardiology
cardiooncology
cancer
cardiotoxicity
pathogenesis of cardiotoxicity
diagnosis of cardiotoxicity
suppression of cardiotoxicity
title Cardiotoxicity of Anticancer Drugs
title_full Cardiotoxicity of Anticancer Drugs
title_fullStr Cardiotoxicity of Anticancer Drugs
title_full_unstemmed Cardiotoxicity of Anticancer Drugs
title_short Cardiotoxicity of Anticancer Drugs
title_sort cardiotoxicity of anticancer drugs
topic oncology
cardiology
cardiooncology
cancer
cardiotoxicity
pathogenesis of cardiotoxicity
diagnosis of cardiotoxicity
suppression of cardiotoxicity
url https://www.antibiotics-chemotherapy.ru/jour/article/view/1190
work_keys_str_mv AT imaiborodin cardiotoxicityofanticancerdrugs
AT aoshumeikina cardiotoxicityofanticancerdrugs
AT vimaiborodina cardiotoxicityofanticancerdrugs
AT sekrasilnikov cardiotoxicityofanticancerdrugs